June 18, 2024

TriHealth Cancer & Blood/Precision Medicine Institute team had four abstracts in Chicago at the American Society of Clinical Oncology (ASCO) international meeting, June 1-4, in Chicago. Abstracts focused on accelerating cancer research and clinical trial engagement, authored by Dr. James Maher, Jason Claes and the TCBI/PMI team. Additional work on precision oncology discrete genomic data in the electronic medical record are also highlighted. TriHealth Precision Oncology team received recognition for AI application utilizing TempusNext to address care gaps in lung cancer care. This collaboration with the innovative multidisciplinary Lung team overseen by Dr. Parchman and Karen Huelsman ensures that all resectable stage IB-III NSCLC patients undergo biomarker testing in alignment with NCCN guidelines.

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. The annual ASCO conference in Chicago is the premier scientific event for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide. More than 30,000 people attend annually. We had the opportunity to showcase the good work being done at TriHealth at this international meeting.

In attendance at ASCO ’24 were James Maher, MD, Leanne Budde, MD, Jason Claes, Karen Huelsman, and Mindy O’Connor (pictured above, right; Dr. Budde not pictured).

Abstract: TriHealth Cancer Institute’s Collaboration with the Tempus AI TIME Program Impact on Clinical Trial Operations and Enrollment

Abstract: Accelerating Cancer Research Trial Startup In The Community Setting: A Quality-Improvement Study

Pictured: Jason Claes in front of poster with James Maher and Mindy O'Connor

TriHealth and TEMPUS teams